Ajay Gautam

Biomedical Innovation in Emerging Markets
Ajay Gautam
BioPharma LatAm
November 2014
Mexico
Mumbai to Shanghai, via NY, Mexico and Dubai
1998
2009
2006
IMED Biotech Unit | Scientific Partnering & Alliances
2012
AstraZeneca is a global business, strong in

Emerging Markets
Sales in over
50,000
100 countries
employees
Manufacturing in
Research across
16 countries
3 continents
$25.7bn sales
Approx. $4bn
2013, Full Year Results
invested in R&D annually
#2
In China
Emerging Markets
$5.4bn sales
2013, Full Year Results
We are accelerating our focus on building a

competitive pipeline in our 3 core therapy areas
Oncology
Respiratory, Inflammation,
Autoimmune
Cardio-Metabolism
Content
Core TAs
Biologics
Small Molecules
Immunotherapies
Protein
engineering
We push the boundaries of science to deliver life-changing medicines
We have increased our proximity to bioscience

clusters and co-located at 3 strategic sites
Gaithersburg
Cambridge
Mlndal
Co-locate around
biologics/specialty care
Co-locate R&D in worldclass science cluster
Leverage historical strength

Respiratory and CV/Met
New site in Cambridge,

close proximity to University of
Cambridge and world class UK
bioscience community
Connections to Karolinska
Institute & Medicon Valley
Proximity to NIH,
Johns Hopkins
Topics
Innovation in emerging markets
A few case studies
AZ fostering innovation in emerging markets
Looking forward
Emerging markets innovation has improved in

recent years
Private & government funding for R&D
Increased
funding
8x increased funding in 5 yrs

Skolkovo, Rusnano, RVC, etc.
BNDES, state funding, VCs
Improved
capabilities
Bio-med bases, certified clinical sites

Strong academic institutions
Publications in high impact journals
Expanded
talent pool
Large number of science PhDs

Overseas returnees
Better growth opportunities
Stronger
IP
- China:
- Russia:
- Brazil:
IP improvements for drugs

Increasing patents from EM companies /
academics
but unique challenges remain in spite of

progress
Innovation
culture
Traditional focus on generics

Shift philosophy to innovation
Scientific
expertise
Need to build expertise in

Biology & Translational Science
Business model
Long lead times, cash flow needs

VCs/Capital markets
Innovation
ecosystem
Ecosystems like Silicon Valley,

Boston, Cambridge, UK nonexistent or at very early stages
Talent pool
Depth and breadth of talent

needs to be built
Emerging markets represent a diverse innovation

landscape
Gautam, A and Yang, S. 13, 646-647 (2014)
Biomedical funding in emerging markets is

increasing
10
Multi-facet aspects need to come together for

building R&D ecosystems
Innovation
IP
11
R&D ecosystems are still evolving

# of publication University rankings
China
Israel
Korea
Singapore
High
Moderate
Low
12
China
Israel
Korea
Singapore
Russia
Brazil
India
Brazil
Turkey
Mexico
S Africa
Poland
India
Russia
Turkey
Mexico
S Africa
Poland
# of PhD
# of patents
# of clinical trials
China
India
Russia
China
Korea
Brazil
Russia
China
Korea
Israel
Brazil
Poland
Brazil
S Africa
Mexico
India
Israel
S Africa
India
Russia
Israel
Korea
Singapore
Poland
Turkey
Turkey
Mexico
Singapore
Poland
Turkey
S Africa
Mexico
Singapore
Topics
A few case studies
Looking forward
13
Zhangjiang Hi-Tech Park, Shanghai: A leading R&D

hub
1992
Today
14
Israel is a leading innovation cluster
Office of
Chief
Scientist
15
Early stage
funding
Korea: Building strength in translational sciences
Korea Drug Development Fund (KDDF)

16
Singapore transitioned to an innovation hub
17
Strong government support, FDIs

Leading academic research
Large talent pool
Venture funding
Topics
A few case studies
Looking forward
18
AZ fostering innovation in Emerging Markets

Korea
Russia
Taiwan
Israel
19
China
Leading personalized cancer research with Petrov

Institute in Russia
N. N. Petrov
Institute of Oncology
1st of its kind research collaboration in Russia
Better understand disease mutations in Russian patients

Petrov is oldest and largest oncology center in Russia
One of largest archival tumor samples in Europe

1 Million+ samples, from over 270,000 patients
20
Cardiac regeneration research with SIBS in China
Research at Shanghai Institute of Biological Sciences (SIBS)

in partnership with AstraZeneca colleagues in Sweden
Understand how newly formed coronary vessels first

develop
Recent publication in Science
21
Translational oncology research with KHIDI in

Korea
Pre-clinical and translational oncology projects
4 projects per year for 3 years, initiated from March 2014

KHIDI to coordinate solicitation of proposals from Korea
local researchers
22
Open innovation with NRPB in Taiwan
Open innovation initiative at AZ

Team up with NRPB in Taiwan to explore new indications and
unmet medical needs with academic researchers
Joint efforts to evaluate proposals from academics and funding

provided from NRPB for R&D
20 compounds provided for drug repurposing
23
Accessible through an Open Innovation Website
http://openinnovation.astrazeneca.com
24
Open Innovation offerings across all stages of

research
Clinical Compound Bank
Patient-ready compounds with evidence of human target coverage and manageable tolerability are
being offered for novel clinical and translational research
Pharmacology Toolbox
Compounds with optimised pharmacological properties are available for preclinical research to explore
novel disease biology and advance scientific knowledge
Target Innovation
Do you have an innovative target idea for a drug discovery project? We may be able to help you
validate your idea, by providing access to our compound library
25
Open Innovation offerings across all stages of

research
New Molecule Profiling
Sophisticated cheminformatics and screening technologies are offered to explore the properties and
therapeutic innovation potential of novel compounds
R&D Challenges
To expand our problem solving ecosystem, we are sharing key R&D hurdles and looking to collaborate
with and reward those who bring innovative solutions
Suggestion Box
Do you have an idea, technology, or suggestion that fits outside of the above mentioned collaboration
offerings?
26
Topics
A few case studies
Looking forward
27
Predicting the future

One may underestimate the long term changes
Crystal ball gazing

In the short term, people tend to grossly overestimate what they
can do in the long term, however, 25 years or greater Id say,
people underestimate what they can do. (1)
- Leroy Hood
28
1987
1994
2000
2012
29
30

Ajay Gautam

Enviado por

Dados do documento

Direitos autorais

Formatos disponíveis

Compartilhar este documento

Compartilhar ou incorporar documento

Opções de compartilhamento

Você considera este documento útil?

Este conteúdo é inapropriado?

Direitos autorais:

Formatos disponíveis

Ajay Gautam

Enviado por

Direitos autorais:

Formatos disponíveis

Biomedical Innovation in Emerging Markets

Mumbai to Shanghai, via NY, Mexico and Dubai

IMED Biotech Unit | Scientific Partnering & Alliances

AstraZeneca is a global business, strong in

2013, Full Year Results

invested in R&D annually

IMED Biotech Unit | Scientific Partnering & Alliances

We are accelerating our focus on building a

We push the boundaries of science to deliver life-changing medicines

IMED Biotech Unit | Scientific Partnering & Alliances

We have increased our proximity to bioscience

Co-locate R&D in worldclass science cluster

Leverage historical strength

New site in Cambridge,

IMED Biotech Unit | Scientific Partnering & Alliances

Innovation in emerging markets

A few case studies

AZ fostering innovation in emerging markets

IMED Biotech Unit | Scientific Partnering & Alliances

Emerging markets innovation has improved in

8x increased funding in 5 yrs

Bio-med bases, certified clinical sites

Large number of science PhDs

IP improvements for drugs

IMED Biotech Unit | Scientific Partnering & Alliances

but unique challenges remain in spite of

Traditional focus on generics

Need to build expertise in

Long lead times, cash flow needs

Ecosystems like Silicon Valley,

Depth and breadth of talent

IMED Biotech Unit | Scientific Partnering & Alliances

Emerging markets represent a diverse innovation

Gautam, A and Yang, S. 13, 646-647 (2014)

IMED Biotech Unit | Scientific Partnering & Alliances

Biomedical funding in emerging markets is

IMED Biotech Unit | Scientific Partnering & Alliances

Multi-facet aspects need to come together for

IMED Biotech Unit | Scientific Partnering & Alliances

R&D ecosystems are still evolving

IMED Biotech Unit | Scientific Partnering & Alliances

Innovation in emerging markets

A few case studies

AZ fostering innovation in emerging markets

IMED Biotech Unit | Scientific Partnering & Alliances

Zhangjiang Hi-Tech Park, Shanghai: A leading R&D

IMED Biotech Unit | Scientific Partnering & Alliances

Israel is a leading innovation cluster

IMED Biotech Unit | Scientific Partnering & Alliances

Korea: Building strength in translational sciences

Korea Drug Development Fund (KDDF)

IMED Biotech Unit | Scientific Partnering & Alliances

Singapore transitioned to an innovation hub

Strong government support, FDIs

IMED Biotech Unit | Scientific Partnering & Alliances

Innovation in emerging markets

A few case studies

AZ fostering innovation in emerging markets

IMED Biotech Unit | Scientific Partnering & Alliances

AZ fostering innovation in Emerging Markets

IMED Biotech Unit | Scientific Partnering & Alliances

Leading personalized cancer research with Petrov

1st of its kind research collaboration in Russia

Better understand disease mutations in Russian patients